What Is MariTide? Structure, Research and Status

MariTide is Amgen's investigational obesity medicine maridebart cafraglutide, an antibody carrying two GLP-1 peptides, and FDA has not approved it.

Basics9 min read

Key takeaway

Maridebart cafraglutide is a fully human antibody against the GIP receptor. A modified GLP-1 peptide is attached to each of its two heavy chains. In a 52-week Phase 2 trial of 592 adults, mean body weight fell 12.3% to 16.2% in the obesity cohort, versus 2.5% with placebo. Gastrointestinal events were common. Phase 3 results have not been reported.

At a glance

Article typeBasics
Main guideTirzepatide: complete guide
Regulatory statusFDA-approved“Tirzepatide is the first FDA-approved dual agonist” (Tirzepatide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited7 in this article · 48 across 20 articles on Tirzepatide
ProductTirzepatide product page

What is MariTide is a common question because it targets the same two receptors as tirzepatide, but acts the opposite way at one. It activates the GLP-1 receptor and blocks the GIP receptor. Amgen published its first human results in 2024, and Phase 3 trials are under way.

Quick answer: MariTide is the name Amgen uses for maridebart cafraglutide, coded AMG 133 in early studies. It is a large protein drug built from an antibody and two peptides, not a classic peptide. It is investigational: FDA has not approved it for any use, and what is known about it comes from clinical and animal studies.

Is MariTide a peptide?

Not in the usual sense. MariTide is an antibody-peptide conjugate (Véniant et al., 2024). A fully human antibody that blocks the GIP receptor carries two copies of a modified GLP-1 peptide. Amino acid linkers join them.

The antibody makes up most of the molecule. Its registered description lists two heavy chains of 450 amino acids and two light chains of 214. It is an IgG1-kappa antibody made in Chinese hamster ovary cells (PubChem substance record). FDA regulations define a protein as an amino acid polymer longer than 40 amino acids (21 CFR 600.3). By that definition, MariTide as a whole is a protein carrying peptide parts (see what peptides are).

The Phase 1 paper reported an average molecular weight of 153,514 daltons. That is about 32 times the 4,813.53 daltons listed for tirzepatide on the Mounjaro label.

According to the PubChem record, each peptide is human GLP-1(7-37) with four amino acid changes. Position 8 carries aminoisobutyric acid (Aib), and positions 16, 22 and 36 carry tyrosine, glutamic acid and glycine. A glycine-serine linker bonds each peptide to an engineered cysteine on an antibody heavy chain.

Table 1

Is MariTide a peptide

FeatureMaridebart cafraglutide (MariTide)TirzepatideSource
Molecule typeHuman IgG1 antibody with two modified GLP-1 peptides attachedSingle modified peptide based on the GIP sequence, with a C20 fatty diacidPubChem; Mounjaro label
Average molecular weight153,514 Da4,813.53 DaVéniant et al., 2024; Mounjaro label
Action at the GIP receptorBlocks itActivates itVéniant et al., 2024; Mounjaro label
Action at the GLP-1 receptorActivates it through the attached peptidesActivates itVéniant et al., 2024; Mounjaro label
How it stays in circulationAntibody size reduces kidney filtration; the FcRn receptor recycles antibodiesFatty diacid binds albumin, a blood proteinWu et al., 2026; Mounjaro label
Half-life in humansAbout 14 to 16 days for the intact moleculeAbout 5 daysVéniant et al., 2024; Mounjaro label
FDA statusInvestigational; not approvedApproved in 2022 (Mounjaro) and 2023 (Zepbound)Drugs@FDA

Where did MariTide come from?

Amgen researchers built MariTide on genetic and animal findings about the GIP receptor (GIPR). The receptor appeared in several genome-wide association studies of body weight, and mice lacking it resisted diet-induced obesity (Killion et al., 2018).

In that 2018 work, a GIPR-blocking antibody protected diet-induced obese mice from weight gain. A version against the human receptor had a larger effect in obese monkeys. Pairing the antibodies with GLP-1 receptor agonists increased weight loss in both species.

A 2026 Amgen chemistry paper describes how the final molecule was chosen (Wu et al., 2026). The team tested several antibody attachment sites and GLP-1 peptide variants. In monkeys, attachment stretched the apparent half-life of the GLP-1 portion from minutes to more than 9 days. The chosen site gave lower potency in cell tests but the most stable molecule. Amgen sponsored all trials described below.

How does MariTide work in the body?

The attached peptides activate the GLP-1 receptor, the target of semaglutide and other GLP-1 medicines. The antibody binds the GIP receptor and blocks it. Cell-based tests in the Phase 1 paper confirmed both activities. Vitrapep's pages on GLP-1 and GIP explain the two natural hormones.

Tirzepatide takes the opposite approach at the GIP receptor: its label describes a molecule that activates both receptors. Both strategies have lowered body weight in human trials. A 2026 review by Davies, Holst and colleagues calls this a paradox. It also notes a lack of human evidence that activating or blocking GIPR alone reduces appetite.

Explanations are being studied in animals and cells. In Amgen mouse and cell work, long exposure to a GIPR activator desensitized fat-cell receptors, mimicking a blocker (Killion et al., 2020). A separate group compared a GIPR agonist with a different GIPR antagonist, not MariTide, in obese male mice. Both reduced food intake and weight, but only the antagonist lowered insulin sensitivity versus pair-fed mice (Davies et al., 2026).

The Phase 1 authors suggested that MariTide is too large to cross the blood-brain barrier, and may act where both receptors sit outside it. That is an interpretation, not a measured human finding.

In the same paper's animal work, a mouse-specific stand-in molecule lowered body weight, food intake, glucose, insulin and lipids in obese mice. In obese cynomolgus monkeys, MariTide itself reduced body weight, energy intake, triglycerides, insulin and cholesterol over six weeks.

What did the human trials show?

The Phase 1 trial was randomized, double-blind and placebo-controlled. It enrolled adults aged 18 to 65 with a body mass index of 30 to 40 and an HbA1c of 6.5% or lower. The paper reported 75 participants; the registry lists 110, including exploratory cohorts. Safety was the primary end point, and weight was exploratory. In the highest repeated-dose cohort, weight was still down by up to 11.2% at 150 days after the last treatment.

The Phase 2 trial was double-blind, randomized, placebo-controlled and dose-ranging, with 11 groups in two cohorts (Jastreboff et al., 2025). It enrolled 592 adults, with a mean BMI of 37.9 in the obesity cohort and 36.5 in the diabetes cohort. Its results in Table 2 count participants whether or not they stayed on treatment.

Table 2

What did the human trials show

StudyDesignPopulation and sizeDurationMain reported result
Phase 1, NCT04478708Randomized, double-blind, placebo-controlled75 adults with obesity in the reported cohortsFollow-up up to 207 daysHighest repeated-dose cohort: weight fell 14.5% by day 85, versus a 1.5% gain with placebo
Phase 2, NCT05669599, obesity cohortRandomized, double-blind, placebo-controlled, dose-ranging465 adults with obesity52 weeksWeight fell 12.3% to 16.2%, versus 2.5% with placebo
Phase 2, NCT05669599, diabetes cohortSame trial, separate cohort127 adults with obesity and type 2 diabetes52 weeksWeight fell 8.4% to 12.3%, versus 1.7%; HbA1c fell 1.2 to 1.6 points, versus a 0.1 rise
Phase 2, NCT06660173Randomized, double-blind, placebo-controlled409 adults with type 2 diabetesHbA1c end point at week 24No peer-reviewed results in PubMed as of November 18, 2026

The Phase 2 trial had no active comparator, so it cannot show how MariTide compares with any other medicine.

What side effects have been reported?

MariTide has no FDA label or boxed warning, so safety information comes from trial publications and registry results.

In Phase 1, nausea and vomiting were the most common adverse events. They were generally mild and resolved within 48 hours. In the repeated-dose cohorts, nausea occurred in 17 of 20 participants on MariTide and 1 of 6 on placebo. Vomiting occurred in 15 of 20 and 0 of 6.

Among those who received at least two treatments, 68% had gastrointestinal events after the first and 9% after later ones. Four participants in the highest repeated-dose cohort withdrew before their second treatment after mild gastrointestinal events.

The paper reported no severe or serious treatment-emergent adverse events. Registry results for all 110 enrolled participants list no serious adverse events and no deaths. Heart rate rose within the normal range, without a dose pattern. Fasting glucose fell, but no hypoglycemia events were reported.

The Phase 2 abstract reported that gastrointestinal adverse events were common. They were less frequent in arms that began at a lower starting level and stepped up gradually. The authors reported no unexpected safety signals. The abstract gives no event rates, and "not reported in the abstract" does not mean "none occurred."

Long-term and rare risks remain unknown.

What Phase 3 trials are under way?

Amgen calls its Phase 3 program MARITIME. MARITIME-1 and MARITIME-2 began in March 2025. On November 18, 2026, ClinicalTrials.gov listed 12 Amgen-sponsored Phase 3 studies of the drug. Table 3 shows the main efficacy and outcome trials.

Table 3

What Phase 3 trials are under way

TrialPopulationDesign and sizePrimary end pointEstimated primary completion
MARITIME-1Adults with obesity or overweight, without type 2 diabetesDouble-blind, placebo-controlled; 3,853 enrolledPercent change in body weight at week 72January 2027
MARITIME-2Adults with obesity or overweight and type 2 diabetesDouble-blind, placebo-controlled; 1,105 enrolledPercent change in body weight at week 72January 2027
MARITIME-CVAtherosclerotic cardiovascular disease with overweight or obesityDouble-blind, placebo-controlled; about 12,800 plannedTime to cardiovascular death, heart attack or ischemic stroke, plus a broader compositeJune 2028
MARITIME-HFHeart failure with preserved or mildly reduced ejection fraction, and obesityDouble-blind, placebo-controlled; about 5,056 plannedTime to cardiovascular death or heart failure eventsJune 2028
MARITIME-T2D-3Type 2 diabetes on metformin, with or without an SGLT2 inhibitorOpen-label, versus semaglutide; about 1,300 plannedChange in HbA1c at week 68 (noninferiority)September 2028

Amgen's November 3, 2026 update said MARITIME-CV and two sleep apnea trials (OSA-1, OSA-2) had completed enrollment. Two more Phase 3 type 2 diabetes studies were due to start in the fourth quarter of 2026.

What is MariTide's regulatory status?

Maridebart cafraglutide is not approved by FDA for any use. A search of openFDA's Drugs@FDA data on November 18, 2026 returned no record for it. Its FDA unique ingredient identifier (Z24U3U73HN) and CAS number (2760218-55-9) are substance registrations, not approvals.

Vitrapep does not sell maridebart cafraglutide; this page is a reference summary of published research and regulatory information. A research-use label on any product does not make it an approved medicine or legal for people. See research peptides and human-use risks.

How does MariTide relate to other incretin medicines?

The tirzepatide complete guide covers that medicine's label and trials. The GLP-1 class overview covers the approved peptide medicines.

These molecules cannot be ranked from the trials above. Populations, durations, comparators and analyses differ. No registered MariTide trial on ClinicalTrials.gov compares it head to head with tirzepatide. See how to evaluate peptide research and how to find a peptide clinical trial.

Frequently asked questions

Is MariTide a peptide?

Not in the usual sense. It is an antibody carrying two modified GLP-1 peptides, and FDA's definition makes the whole molecule a protein.

Is MariTide FDA-approved?

No. FDA has not approved maridebart cafraglutide for any use. Amgen is testing it in Phase 3 trials.

How is MariTide different from tirzepatide?

Tirzepatide activates both the GLP-1 and GIP receptors. MariTide activates the GLP-1 receptor and blocks the GIP receptor. It is also about 32 times heavier.

What did the Phase 2 trial find?

Over 52 weeks, mean body weight fell 12.3% to 16.2% in adults with obesity, versus 2.5% with placebo. In adults with obesity and type 2 diabetes, it fell 8.4% to 12.3%, versus 1.7%.

What side effects have been reported for MariTide?

Nausea and vomiting were most common in Phase 1, mostly mild and early. Phase 2 reported common gastrointestinal events and no unexpected safety signals.

When are Phase 3 results expected?

ClinicalTrials.gov lists estimated primary completion for MARITIME-1 and MARITIME-2 in January 2027. The cardiovascular and heart failure trials list June 2028.

What to know now

  • MariTide (maridebart cafraglutide, AMG 133) is an Amgen antibody against the GIP receptor carrying two modified GLP-1 peptides.
  • It activates the GLP-1 receptor and blocks the GIP receptor, the reverse of tirzepatide at the GIP receptor.
  • In Phase 2, mean body weight fell 12.3% to 16.2% at 52 weeks in adults with obesity, versus 2.5% with placebo.
  • FDA has not approved it for any use.

What we’re watching

  • Results of MARITIME-1 (NCT06858839) and MARITIME-2 (NCT06858878), with primary completion estimated for January 2027.
  • MARITIME-CV and MARITIME-HF, the outcome trials, with primary completion estimated for June 2028.
  • Peer-reviewed results of the 409-participant Phase 2 type 2 diabetes trial (NCT06660173).
  • The two additional Phase 3 type 2 diabetes studies Amgen said would start in late 2026, and any future FDA filing.

Also in the library

More for endocrine & metabolism

All 48 compounds for endocrine & metabolism

Sources: Véniant 2024, Nature Metabolism, 6; Jastreboff 2025, New England Journal of Medicine, 393; Wu 2026, Journal of Medicinal Chemistry, 69; Killion 2018, Science Translational Medicine, 10; Killion 2020, Nature Communications, 11; Davies 2026, Diabetes, Obesity and Metabolism, 28; Davies 2026, Annual Review of Nutrition, 46; National Center for Biotechnology Information 2026; U.S. Food and Drug Administration 2026; Eli Lilly and Company 2026; U.S. Food and Drug Administration 2026; Amgen 2025; Amgen 2025; Amgen 2026. All 14 citations

Back to the research library

References

  1. Véniant, M. M., Lu, S. C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., et al. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism, 6(2), 290-303. https://pubmed.ncbi.nlm.nih.gov/38316982/
  2. Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., et al. (2025). Once-monthly maridebart cafraglutide for the treatment of obesity: A phase 2 trial. New England Journal of Medicine, 393(9), 843-857. https://pubmed.ncbi.nlm.nih.gov/40549887/
  3. Wu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K., et al. (2026). Discovery of AMG 133, a glucose-dependent insulinotropic polypeptide receptor antagonist and glucagon-like peptide 1 receptor agonist antibody-drug conjugate for the treatment of obesity. Journal of Medicinal Chemistry, 69(8), 9348-9362. https://pubmed.ncbi.nlm.nih.gov/41941715/
  4. Killion, E. A., Wang, J., Yie, J., Shi, S. D., Bates, D., Min, X., et al. (2018). Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Science Translational Medicine, 10(472), eaat3392. https://pubmed.ncbi.nlm.nih.gov/30567927/
  5. Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., et al. (2020). Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications, 11(1), 4981. https://pubmed.ncbi.nlm.nih.gov/33020469/
  6. Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., et al. (2026). A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice. Diabetes, Obesity and Metabolism, 28(2), 1160-1167. https://pubmed.ncbi.nlm.nih.gov/41287212/
  7. Davies, I., Holst, J. J., Rosenkilde, M. M., & Tan, T. M. M. (2026). The paradox and future of GLP-1/GIP combination therapies: Efficacy and mechanisms. Annual Review of Nutrition, 46(1), 387-414. https://pubmed.ncbi.nlm.nih.gov/42166683/
  8. National Center for Biotechnology Information. (2026). PubChem substance record for SID 478838466, maridebart cafraglutide (deposited from FDA's Global Substance Registration System). https://pubchem.ncbi.nlm.nih.gov/substance/478838466
  9. U.S. Food and Drug Administration. (2026). 21 CFR 600.3, Definitions (protein definition, paragraph (h)(6)). Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-A/section-600.3
  10. Eli Lilly and Company. (2026). MOUNJARO (tirzepatide) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  11. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 215866, Mounjaro (tirzepatide). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
  12. Amgen. (2025). Evaluation of maridebart cafraglutide in adult participants without type 2 diabetes mellitus who have obesity or are overweight (MARITIME-1). ClinicalTrials.gov identifier NCT06858839. https://clinicaltrials.gov/study/NCT06858839
  13. Amgen. (2025). Evaluating the impact of maridebart cafraglutide on cardiovascular outcomes in participants with atherosclerotic cardiovascular disease and overweight or obesity (MARITIME-CV). ClinicalTrials.gov identifier NCT07037433. https://clinicaltrials.gov/study/NCT07037433
  14. Amgen. (2026, November 3). Amgen reports third quarter 2026 financial results [Press release]. https://www.amgen.com/newsroom/press-releases/2026/11/amgen-reports-third-quarter-2026-financial-results